Skye Bioscience - Peter Collum to serve as CFO of Fibrx Therapeutics

Skye Bioscience has announced that Peter Collum will serve as Chief Financial Officer (CFO) of Fibrx Therapeutics, a clinical-stage biotechnology company focused on developing novel therapeutics for unmet medical needs. The appointment reflects Skye Bioscience’s ongoing commitment to strengthening its leadership team as it advances its pipeline of innovative drug candidates.

Collum brings extensive experience in financial leadership across the biopharmaceutical industry, having previously held executive roles at multiple public and private companies. His background includes strategic financial planning, capital raising, and operational management, positioning him to support Fibrx Therapeutics during a critical phase of development.

This leadership change follows recent executive appointments in the biotech sector, including Ryan Maynard joining Foghorn Therapeutics as CFO, and Jenn Larson assuming the CFO role at Bicara Therapeutics. These moves highlight a broader trend of companies reinforcing their financial leadership to support clinical development and long-term growth.

Skye Bioscience did not disclose further details regarding Collum’s prior experience or the timeline for his transition. Investors are advised to monitor the company’s future announcements for additional insights into its financial strategy and operational progress.